

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/13896 A1

(51) International Patent Classification⁷: A61K 9/28, 9/30

Jerusalem (IL). FRYDMAN, Norbert [IL/IL]; 3 Jericho Street, 52356 Ramat Gan (IL).

(21) International Application Number: PCT/US00/22929

(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(22) International Filing Date: 21 August 2000 (21.08.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

— With international search report.

(30) Priority Data:
60/150,514 24 August 1999 (24.08.1999) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except BB, US*): TEVA PHARMACEUTICAL INDUSTRIES, LTD. [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah-Tiqva (IL).

(71) Applicant (*for BB only*): TEVA PHARMACEUTICALS USA, INC. [US/US]; 650 Cathill Road, Sellersville, PA 18960 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GALLILI, Gilad [IL/IL]; 32 Shear Yashuv Street, Ramot 02, 97280



WO 01/13896 A1

(54) Title: A VACCINE COMPOSITION AND METHOD OF USING THE SAME

(57) Abstract: The present invention relates to a stable compacted, compressed or hard tableted vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.

A VACCINE COMPOSITION AND METHOD OF USING THE SAME

5

This application is a continuation-in-part and claims priority of U.S. Provisional Application No. 60/150,514, filed August 24, 1999. The contents of the above-identified application are hereby incorporated by reference into this
10 application.

Through this application, various references are identified by authors and full citations. Disclosure of these publications in their entireties are hereby incorporated by
15 reference into this application to more fully describe the state of the art to which this invention pertains.

Field of the Invention

20 The present invention relates to a stable compacted, compressed or tableted vaccine composition having a dense solid form, comprising one or more freeze dried (lyophilized) antigenic components and a dissolution aid. This stable dense vaccine composition retains all of the advantageous properties of the lyophilized components thereof, including
25 titer stability and solubility while further providing complete and rapid dissolution in a diluent. Moreover, the vaccine composition of the present invention avoids the disadvantages of prior known lyophilized preparations. A
30 method for immunizing a subject using the stable vaccine composition to form a vaccine solution is also provided.

- 2 -

Background of The Invention

It is well-known, that biological materials in solutions such as vaccines are susceptible to varying influences including
5 heat, oxidizing reagents, salts, pH, light, and proteolytic enzymes.

Several methods are known for reducing these detrimental effects in general and more specifically to improve the
10 stability of a vaccine especially during storage. For example, storage below 0°C, and as low as -70°C, in a freezer is a well-known method. At even lower temperatures, e.g. in liquid nitrogen, many biological materials including living cells can successfully be stored for many years. However,
15 such methods are not always convenient in those situations, for example, that involve the inoculation of free-ranging livestock.

Lyophilizing or freeze drying is another known way of
20 conserving live cells and viruses for use as vaccines. During freeze drying, the solution containing the biological material is first frozen and the water is then evaporated by sublimation, usually under high vacuum and sub-zero temperatures. Previous approaches have used freeze drying
25 or other techniques to formulate viral vaccines but still pose other difficulties with respect to preparation and administration of a stable final dosage form.

For example, U.S. Patent No. 4,251,509 (Hanson and Abegunde)
30 discloses a stable particulate viral vaccine intended to be orally administered to free ranging livestock in a dry state. However, the disclosed dosage form is not freeze dried but prepared by concentrating and extruding a paste dried to form pellets.

- 3 -

Antioxidants, the selection of which will depend on the particular virus, are required to promote thermostability. Such a formulation may be more complicated to prepare and is not particularly well-suited for those instances when it is
5 desired to dissolve the vaccine before immunization.

U.S. Patent Nos. 3,458,621 and 3,608,030 (Tint) disclose the use of freeze dried virus preparations to prepare a tablet for oral administration for the immunization of the
10 intestinal tract. However, the tablets prepared are for oral administration and are provided with an enteric coating to delay disintegration. During in-vitro testing they did not rapidly disintegrate and were found to disintegrate only "within 25 minutes" with simulated intestinal fluid.
15 Moreover, the time to disintegrate was measured in simulated intestinal fluid thereby discounting effects of the enteric coating. In addition, Tint further emphasizes that unless the tablets are "press coated" they will lose their titer as shown by a comparison between press coated and non-press
20 coated tablets. Tint notes that the non-press coated tablets "not only failed to elicit an antibody response in all the antibody-negative individuals, but, in addition, the magnitude of the titer rise was significantly smaller." (See column 4, line 40).
25

PCT Publication No. WO 99/21579 (Seager, et al.) assigned to the R.P. Scherer Corp. discloses a "fast" dispersing composition for a veterinary vaccine such as against New Castle disease that is freeze dried and "loosely compacted."
30 The dosage form is disclosed as an "open matrix network", such as a "solid foam" referenced from U.S. Patent No. 4,371,516 (counterpart to UK Patent No. 1,548,022), as opposed to a compressed form or hard tableting. Moreover, the vaccines are directed to oral administration and targeted
35 towards retention at mucosal tissue. Adjuvants serve to provide sufficient residence time for absorption thereon. The

- 4 -

disclosed vaccine formulation does not provide for preparation of a liquid dosage for later immunizing, nor a means to readily form a stable, measured vaccine solution for administration as a liquid dose, nor for providing a stable 5 compressed or hard tableted lyophilisate to facilitate later administration thereof.

U.S. Patent No. 5,587,180 (Allen, Jr. et al) describes a process for making a particulate support matrix for a rapidly 10 dissolving tablet. The process teaches away from freeze drying and uses standard spray-drying techniques. The particulate support matrix is suitable for dosage administration when placed into the oral cavity. Moreover, no stable vaccine formulation is provided as a vaccine 15 solution in a liquid dosage form.

U.S. Patent No. 5,336,666 (Neway et al.) discloses a freeze dried liquid vaccine that may form a tablet to be reconstituted in liquid form. However, the vaccine is 20 limited to a polar glycopeptide of a particular bacterium and does not provide for complete or rapid dissolution.

Although freeze drying of biological material can be performed according to lyophilizing procedures well known to 25 one skilled in the art to provide a stable vaccine preparation, the titer of a live virus at the end of lyophilization is typically not the same as it was for the solution before the lyophilization process. In general it is not possible to conduct titration before lyophilization 30 as the solution is not stable until it is freeze dried. In addition, the titer will change unpredictably during lyophilization. Consequently, an estimate for the initial titer based on experience is only validated by titration after freeze drying. As a result of all of the above, it is 35 almost impossible to achieve a defined accurate target titer.

- 5 -

If lyophilization has been carried out with the lyophilisate already contained in vials, reworking of the batch is typically not possible, and in some cases a whole batch must be discarded if it is not up to specification.

5

U.S. Patent No. 5,897,852 (Wilderbeek, et al.) attempts to solve such a problem using different "freeze dried bodies" with "lyospheres" to make up for shortfalls in the titer of a lyophilized cake. However, each lyosphere has its own 10 titer thereby necessitating the titration of multiple bodies to arrive at a desired titer. Even in the best case, this method does not achieve the exact required titer as it is only an approximation due to the use of combined bodies to 15 achieve the target titer. Furthermore, the production of lyospheres is relatively difficult compared with the more straightforward freeze drying of solutions to produce a cake or powder. Additionally, a special matrix is often required to prevent the lyosphere material from being pulverized after 20 drying. In general, the method requires the preparation of separate solutions each having a different titer, additives and adjuvants. The method does not solve the problem that 25 the titer for a batch of live virus is rarely homogenous, and varies from one vial to the next, particularly over the areas of the cold plates in the lyophiliser. Therefore, determination of the number of lyospheres needed per vial is always an approximation.

Freeze drying may also be useful for vaccines comprising more than one immunogenic component. For example, EP 30 290197A discloses a freeze dried tetravalent vaccine. The procedure discloses the mixing and subsequent freeze drying of four live virus vaccine components.

A disadvantage to current freeze drying techniques for 35 vaccine preparation is that the process is very complex,

- 6 -

having many variables, rendering it notoriously difficult to perform in a reproducible manner to achieve acceptable product and dosage uniformity. This is especially problematic for veterinary vaccines where a large number of 5 doses are freeze dried in one vial. The problem is less common for human vaccine preparation, although equally appreciable where mass inoculation is necessary, for example in military scenarios, or in situations of pandemic infection. For example, a typical single vaccine vial for 10 poultry vaccination comprises either 1000 or 2000 doses, and is registered as such. Before freeze drying, a rough estimation is made about the titer of the material, but the final titer can only be determined after freeze drying, as the titer often decreases rather unpredictably during freeze 15 drying. Furthermore, the raw material of live virus or bacteria cannot usually be kept stable long enough to obtain accurate titer results before freeze drying.

In practice, a container originally comprising more than 2000 20 doses can often turn out to comprise only 1900 doses after freeze drying. In that case, the vial might only be marketable as a 1000 dose vial, since that typically is the only other official registrable dosage. For such a scenario, a 47% waste of material and corresponding increase in costs 25 could occur. This problem is compounded with combination vaccines because the dosage of the component with the lowest titer must be used to characterize the entire batch. As a further disadvantage, when vials intended to provide 2000 single doses are subsequently marketed as 1000 dose vials and 30 used to innoculate 1000 animals, the animals thus dosed are unnecessarily over-exposed. Moreover, deliberately increasing the number of doses before freeze drying is not a satisfactory alternative when some of the vaccine batch is dried more efficiently. In that situation, one simply ends 35 up wasting that material.

- 7 -

These problems will become increasingly important to solve as Registration Authorities currently work toward a registration system where the number of vaccine dose titers are set between well-defined upper and lower limits. Given
5 the many variables in both the production and the freeze drying process, it will be difficult to meet these limits on a large-scale production basis. As indicated, this problem will be even more pronounced when a combination vaccine is required.

10

Yet a further disadvantage to previous freeze dried combination vaccines is that a large number of formulated combinations must be kept in storage. This occurs because the various components in a combination vaccine are typically
15 mixed prior to freeze drying. Thus, for the preparation of a full range of single/multi-component-vaccines against, e.g. two diseases, three different products must be kept in stock; (1) the product comprising anti-A vaccine, (2) the product comprising anti-B vaccine; and (3) the product comprising anti-A and anti-B vaccine. In the case of vaccines against
20 three diseases, seven different vaccines/combinations have to be made and stored. For four diseases, this number mounts to fifteen different vaccines/combinations. Consequently,
25 it is often necessary to provide and maintain a large storage capacity.

U.S. Patent Nos. 5,397,569 and 5,871,748 (Whitfill et al.) disclose a method for producing active immunity against Newcastle Disease virus (NDV) in avian subjects by
30 administering, in-ovo, a vaccine complex comprised of a live vaccine virus and neutralizing antibodies bound thereto. Whitfill discloses that the ratio of virus to the neutralizing antibody or fragment thereof will determine the success of the immunization. However, for such a method to
35 be applied effectively against NDV, a narrow range of values

- 8 -

for that ratio must be maintained so that successful immunization will occur without killing the chicks. Moreover, the unpredictability in the titer using lyophilized NDV (as with other virus preparations) means that methods such as 5 Whitfill's are not easily applicable for NDV. Therefore, a method which could ensure more exact titers of NDV and antibodies for preparing such a vaccine is desired.

Yet another disadvantage to prior vaccine formulations and 10 their methods of production lie in the space-consuming nature of the actual freeze drying process. Typically, lyophilizing a vaccine first requires dispensing the solubilized vaccine into glass vials. The vials are then loosely capped with rubber stoppers and placed on trays in racks in a freeze 15 drying chamber or condenser. It is difficult to concentrate very high doses of solubilized vaccine material in a very small volume.

As a result, the vials typically used in freeze drying for 20 multiple vaccine doses always contain a relatively large volume of fluid. Efficient freeze drying requires that the fluid to be lyophilized exposes a large surface area to the vacuum. Therefore, since only the top of the frozen pellet is in contact with the vacuum, vaccines are freeze 25 dried in relatively large glass bottles or vials, with a wide bottom. These vials are sometimes 5 centimeters high, wherein an additional 2 cm of height is needed for the rubber stoppers. Consequently, the ratio of product material to empty space in the freeze drying apparatus is extremely 30 inefficient leading to a less cost effective production process.

Another disadvantage to conventional compositions for freeze 35 dried vaccines formulated to be contained in glass vials is that the rubber stoppers can hinder free transfer of water

- 9 -

molecules from the vial to the condenser during lyophilization. This can increase the partial pressure of sublimating gases inside the vial, thereby decreasing the efficiency of the lyophilization, as well as increase the
5 risk of collapse of the lyophilized material. Glass also impedes heat transfer to further affect lyophilization efficiency. Formulating a vaccine that would eliminate both glass vials and stoppers by using trays in the lyophilization would increase efficiency. Moreover, freeze drying is very
10 time-consuming. Vaccine components are typically kept just below the freezing point to decrease water sublimation time. However, a longer drying period leads almost inevitably to a decrease of titer. The glassvials with their stoppers and
15 aluminum covers are generally seen as an encumbrance. In production terms they can represent more than 50 percent of the cost of the finished vaccine. In field situations, the diluent must be injected into the vial and the resultant solution extracted and diluted, if necessary for use. This is an inconvenience not always suited to on-site situations,
20 such as in a chicken-shed. It is not uncommon for the operative in these situations to accidentally be selfinjected during this procedure. Yet another disadvantage to such vaccine packaging and preparation is that some of the concentrated solution will remain in the vial. Consequently,
25 it is generally accepted that an overage in the contents is necessary to compensate for non-homogeneity and production losses, as well as losses incurred over storage periods. Glass vials must also be safely disposed of and can result in possible health and environmental hazards.

30

As a result, use of conventional freeze dried vaccine formulations involve complicated preparation techniques which are costly and difficult to implement in the field. Consequently, such conventional vaccine formulations are not well-suited for vaccinations in underdeveloped countries were
35

- 10 -

economic and field conditions do not allow for costly campaigns, or in the case of mass immunizations which may be needed, such as in the defense of biological warfare, or other potential catastrophes or epidemics.

5

What is desired, therefore, is a vaccine formulation which obviates the use of glass vials for administration providing a less costly and bulky packaging alternative. What is also desired is a vaccine formulation and method of use which 10 provides greater dosing accuracy and ease of use while maintaining stability, sterility, solubility and homogeneity for both single and multiple vaccine formulations. A vaccine formulation and improved immunizing method which facilitates more accurate, reproducible and efficient administration can 15 provide the advantages of better field performance, increased safety, cost-effectiveness, less waste, and improved environmental compliance.

20

25

30

35

- 11 -

Summary of the Invention

- Accordingly, it is an object of the invention to provide a vaccine composition and method of immunizing accomplished by
5 simply dissolving a solid, dense stable form of a lyophilized vaccine in a diluent thereby eliminating the need for glass vials, while also allowing for much greater accuracy of dosing and ease of use.
- 10 A further object of the invention is to provide a lyophilized live or inactivated vaccine which is compacted, compressed or tableted as a dense stable solid that will retain its potential immunizing capacity during preparation and for the duration required for sufficient shelf-life of a commercial vaccine.
- 15 A further object of the invention is to provide a lyophilized live or inactivated vaccine which is compacted, compressed or tableted as a dense stable solid which facilitates formulation of in-ovo vaccine preparations and uses thereof.
- 20 A further object of the invention is to provide a lyophilized live or inactivated vaccine which is compacted, compressed or tableted as a dense stable solid which facilitates packaging of vaccines in non-vial containers and use thereof.
- 25 Another object of the invention is to provide a vaccine composition and method of immunizing with greater flexibility in the vaccinations that can be formulated and uses thereof.
- 30 A further object of the invention is to provide a vaccine composition and method of immunizing which reduces the need for excess vaccine material needed to compensate for the inherent inaccuracies in the titer of the packaged vaccine made

- 12 -

according to known methods.

Another object of the invention is to provide a vaccine composition and method of immunizing which allows greater 5 flexibility in the types of vaccine formulations that may be administered.

Yet another object of the invention is to provide a vaccine composition and method of immunizing which facilitates 10 formulation of a multi-dose vaccine solution and uses thereof.

Another object of the invention is to provide a vaccine composition and method of immunizing which facilitates human 15 mass immunization.

Another object of the invention is to provide a vaccine composition and method of immunizing that is suitable and cost-effective for vaccinations in underdeveloped countries, 20 where cost and field conditions do not allow for complicated preparation and costly campaigns.

Yet another object of the invention is to provide a vaccine composition and method of immunizing amenable for use in 25 defense of biological warfare, where mass immunization is a must.

These and other objects may be achieved by the present 30 invention which relates to a stable vaccine composition comprising at least one pre-titrated lyophilized antigenic component and a dissolution aid, wherein the vaccine composition is in the form of a hard tablet. In addition, the present invention also provides a method of immunizing a subject against a disease comprising the steps of: dissolving 35 a vaccine composition with a diluent to form a solution,

- 13 -

wherein the vaccine composition comprises at least one lyophilized antigenic component and a dissolution aid, wherein the vaccine composition is in the form of a hard tablet, and wherein the vaccine composition provides
5 protection against such disease; and administering the resulting solution to the subject in an amount effective to immunize the subject against the disease.

The invention in its particular features will become more
10 apparent from the following detailed description considered with reference to the accompanying examples. The following description will continue to discuss the problems and solutions offered by the present invention as they pertain to veterinary applications. However, the following should in no
15 way be interpreted as being limited thereto or inapplicable to human vaccination.

20

25

30

35

-14-

Detailed Description of the Invention

This invention provides a stable compressed vaccine composition comprising at least one lyophilized antigenic component and a dissolution aid.

In a preferred embodiment of the invention, the vaccine composition is in the form of a hard tablet.

10 In another preferred embodiment of the invention, the composition dissolves completely and rapidly in water.

In a preferred embodiment of the invention, the composition is sterile.

15 In a preferred embodiment of the invention, the dissolution aid is an effervescent agent or pair of agents, a disintegrant, a surfactant, or a solubilizer.

20 In another preferred embodiment of the invention, the effervescent pair comprises a salt and an acid,

25 In another preferred embodiment of the invention, the effervescent pair is citric acid and the salt is a bicarbonate.

In another preferred embodiment of the invention, the vaccine composition comprises a binder and a lubricant.

30 In yet another preferred embodiment of the invention, the composition disintegrates completely and rapidly in water.

35 In another embodiment of the invention, the active material is a pre-titrated lyophilizate that is kept under a dry nitrogen atmosphere below a freezing temperature prior to use.

-15-

In another embodiment of the invention, the lyophilized component comprises up to 80% by weight of the composition.

5 In another preferred embodiment of the invention, the vaccine composition is characterized by complete dissolution within less than 80 seconds upon contact with a diluent.

10 In another preferred embodiment of the invention, complete dissolution of the vaccine composition occurs at a diluent to composition ratio of between 0.5 ml of diluent per 200 mg of composition and 100 ml of diluent per 400 mg of composition.

15 In another preferred embodiment of the invention, the stability of the vaccine composition is characterized by a loss of titer no greater than the difference between $10^{5.7}$ EID₅₀/ml and $10^{5.3}$ EID₅₀/ml after 5 days at 37°C.

20 In another preferred embodiment of the invention, the stability of the vaccine composition is characterized by a loss of titer no greater than the difference between $10^{5.7}$ EID₅₀/ml and $10^{5.3}$ EID₅₀/ml after 9 months at 4°C.

25 In yet another preferred embodiment of the invention, the antigenic component of the vaccine composition is a whole virus, a whole bacterium or a whole microorganism.

In another preferred embodiment of the invention, the antigenic component of the vaccine composition is a live bacterium or a live virus.

30 In a preferred embodiment of the invention, the vaccine composition comprises an indicator of the presence of the antigenic component.

35 In a preferred embodiment of the invention, the indicator is a dye.

-16-

This invention further provides a stable vaccine composition comprising at least one lyophilized antigenic component and a dissolution aid, wherein the vaccine composition is in the form of a hard tablet and the antigenic component comprises
5 a lipopolysaccharide or a protein, whether naturally occurring, recombinant, or modified.

In a another preferred embodiment of the invention, the antigenic component is a live virus selected from the group consisting of: Newcastle Disease virus or bacterium, Newcastle Disease virus VH strain, Infectious Bursal Disease virus, Gumboro Disease virus, fowl pox virus, Laryngotraecheitis virus, Infectious Bronchitis of poultry virus, Gumboro Winterfield virus, Infectious Bronchitis (IB-H120), sheep pox virus, Rinderpest virus, anthrax spores, Salmonella SPP., E.coli., or an admixture of one or more of the foregoing whether naturally occurring, recombinant or modified.
10
15

20 In yet another embodiment of the invention, the antigenic component is selected from the group consisting of: anthrax spores, Salmonella SPP, E. coli, or an admixture of one or more of the forgoing, whether naturally occurring, recombinant or modified.
25

In yet another preferred embodiment of the invention, the antigenic component is a live virus and the composition further comprises neutralizing antibodies against the virus.

30 This invention further provides a method of immunizing a subject against a disease comprising the steps of: dissolving a vaccine composition with a diluent to form a solution, wherein the vaccine composition comprises at least one lyophilized antigenic component and a dissolution aid,
35 wherein the vaccine composition is in the form of a hard tablet, and wherein the vaccine composition provides protection against such disease; and administering the

-17-

resulting solution to the subject in an amount effective to immunize the subject against the disease.

5 In a preferred embodiment of the invention, the dissolving step of the method of immunizing is further characterized by complete dissolution of the vaccine composition.

10 In yet another preferred embodiment of the invention, complete dissolution during the dissolving step of the method of immunizing occurs at a diluent to composition ratio of between 0.5 ml of diluent per 200 mg of composition and 100 ml of diluent per 400 mg of composition.

15 In another preferred embodiment of the invention, the dissolving step of the method of immunizing is further characterized by complete dissolution within less than 80 seconds upon contact with a diluent.

20 In another embodiment of the invention, the administering step comprises injecting the subject with the solution.

25 In another embodiment of the invention, the administering step comprises spraying the subject with an aerosol formed from the solution.

In yet another embodiment of the invention, the administering step comprises applying the solution to the subject in the form of eye drops.

30 In yet another embodiment of the invention, the administering step comprises applying the solution by oral ingestion.

35 In a preferred embodiment of the invention, the method of immunizing is applied to a subject that is an avian animal and the disease is selected from the group consisting of Newcastle Disease, Infectious Bursal Disease, fowl pox, Laryngotracheitis, Infectious Bronchitis of poultry.

-18-

In another preferred embodiment of the invention, the administering step comprises administering a solution to the subject in-ovo.

5 This invention also provides a package comprising the vaccine composition having at least one lyophilized antigenic component and a dissolution aid, wherein the vaccine composition is in the form of a hard tablet or further comprises an indicator of the presence of the antigenic
10 component.

In a preferred embodiment of the invention, the package is a blister pack.

15 In another preferred embodiment of the invention, the package is a sterile syringe.

This invention also provides a sterile syringe comprising a compacted vaccine composition, wherein the vaccine
20 composition comprises at least one lyophilized antigenic component and a dissolution aid.

In one embodiment of the invention, the compacted vaccine composition of the sterile syringe is a compressed
25 composition.

In a preferred embodiment of the invention, the compressed vaccine composition of the sterile syringe is in the form of a hard tablet.

30 This invention further provides a method of immunizing a subject against a disease which comprises adding a diluent to a sterile syringe comprising a compacted vaccine composition, wherein the vaccine composition comprises at least one
35 lyophilized antigenic component and a dissolution aid, or wherein the compacted vaccine composition of the sterile syringe is further characterized as a compressed composition, or wherein the compressed vaccine composition of the sterile

-19-

syringe is in the form of a hard tablet, so as to form a solution in the syringe and administering the resulting solution to the subject.

- 5 Solutions resulting from dissolution of the vaccine composition of the present invention may be administered by any suitable means. The method of immunizing a subject against a disease according to the present invention may employ a number of methods to administer a liquid solution
10 formed by the vaccine composition. Exemplary methods of administration are intramuscular injection, subcutaneous injection, intravenous injection, intra peritoneal injection, eye drop, via drinking water, aerosol, or nasal spray. When the animal to be treated is a bird, the bird may be a newly
15 hatched (i.e., about one day old after hatching), adolescent, or adult bird. The vaccine of the present invention may be useful for administration of birds in ovo, as described in U.S. Patent No. 4,458,630 to Sharma.

20 The freeze dried (lyophilized) pre-titrated vaccine composition of the present invention is understood to be a preparation composed of at least one freeze dried antigenic pre-titrated vaccine component, excipients and optionally various additives that have been compacted or compressed into
25 a dense form.

As used herein, "dense" refers to the vaccine composition having a density greater than 1.0 g/cc. Usually, the density of the vaccine composition will be greater than 1.5 g/cc.
30 Typically, the range of density for the vaccine composition will be from about 1.5 g/cc to 2.5 g/cc.

The vaccine composition may be compacted, compressed, or in the form of a hard tablet.

-20-

As used herein, "compacted" refers to a vaccine composition having a density greater than 1.0 g/cc, but no measurable hardness as measured in Strong-Cobb Units (SCU) and tested for hardness on a ERWEKA Tablet Hardness Tester Model TBH20.

As used herein, "compressed" refers to a vaccine composition having a hardness of at least 2.0 SCU and "hard tablet" refers to a vaccine composition in the form of a tablet or other dense form having a hardness of at least 3.0 SCU.

The compacted, compressed and hard tablets of the vaccine composition can be made on an instrumented MANESTY F3 Single Punch 12mm Flat Beveled or 6mm standard concave punches.

The vaccine composition in the form of a hard tablet was made at a pressures of a maximum of 4 tonnes. The tablets were tested for hardness on a ERWEKA Tablet Hardness Tester Model TBH20 as described above, and were all found to have a hardness greater than 3.0 SCU.

The classic tablet normally associated with therapeutic agents is understood to be such a "tablet". However, it is understood that any compacted or compressed dense form is intended, including those having less frequent use in the pharmaceutical field. For example, large "briquettes" would be suitable should the final application require a large volume of material.

It is understood that a preparation that disintegrates or dissolves "completely" and "rapidly" in a diluent is one that is capable of doing so in pure water even if the intended use is not with pure water, but rather with a solution e.g., saline, or for that matter a non-aqueous vehicle.

-21-

By "completely dissolved" it is understood that no soluble component is left undissolved. By "rapidly disintegrated or dissolved" is understood that disintegration or dissolution is complete within approximately a few minutes or less when
5 a large volume of water is employed for small volume of compressed lyophilized vaccine composition e.g., 100 ml of water for a 400 mg effervescent tablet. The time is increased where the volumes of diluent are comparably decreased. Thus the same tablet might require 70 seconds
10 with a volume of water of 10 ml, and 80 seconds in 2 ml of water.

The disintegration or dissolution time referred to above is the time taken for dissolution or disintegration of a tablet
15 when placed in a measured quantity of water at room temperature without stirring.

By "stable" it is understood that the compositions of the present invention will maintain their (potential) immunizing capacity during preparation and for the duration required for
20 shelf life of a commercial vaccine.

As will be demonstrated by reference to the following examples, a vaccine composition and method of immunization
25 according to the present invention has numerous advantages as has been described herein.

The method of the present invention is generally exemplified as follows for the preparation of a vaccine composition containing 1000 doses of vaccine component. A solution of the vaccine component is lyophilized in trays. The dried material is pulverized. The titer of a homogeneously mixed sample after freeze drying is determined while the lyophilizate is kept under nitrogen in a tightly secured container at - 20°C. If the titer of the lyophilized material
35 is determined to be 625 doses per 100 mg, it suffices to

-22-

weigh out 160 mg of this material per compressed vaccine preparation to arrive exactly at the required titer. The material is then mixed with optional and/or functional additives and the preparation is compressed or tableted. The
5 compressed freeze dried vaccine preparations can then be packaged by any of the methods known to those skilled in the art and/or described herein.

The term excipient is a catch-all term for diluents or
10 vehicles used in the formulation of the vaccine composition. Excipients can include: diluents or fillers, binders or adhesives, dissolution aids, lubricants, antiadherents, glidants or flow promoters, colors, flavors, sweeteners and adsorbents.
15

Specifically, tablet fillers are substances that compromise the bulk of the tablet and primarily act as a carrier. Typical tablet fillers include, but are not limited to, calcium sulfate, calcium phosphate, calcium carbonate,
20 starch, modified starches (carboxymethyl starch, etc.), microcrystalline cellulose, lactose, sucrose, dextrose mannitol and sorbitol.

Tablet filler levels are from about 0% to 90% by weight of
25 the tablet.

Binders act as the "glue" which holds powders together to form granules. Binders include, but are not limited to, natural polymers such as starches or gums acacia, tragacanth
30 and gelatin or synthetic polymers such as PVP and methyl-, ethyl- and hydroxypropylcellulose.

Binder levels are from about 0% to 20% by weight of the composition.
35

-23-

Dissolution aids promote dissolution of the vaccine composition. Typical examples include, but are not limited to effervescent agents, disintegrates, surfactants and solubilizers.

5

Disintegrants cause compressed tablets to break apart. Typical examples include, but are not limited to, starch, microcrystalline cellulose, purified wool starch, alginic acid, sodium starch glycolate guar gum, crosslinked polyvinyl pyrrolidone (PVP), ion exchange resin and celluloses such as methyl-, croscarmellose sodium, sodium carboxymethyl- and hydroxypropylmethyl-.

10 Dissolution aid levels are from about 1% to 95% by weight of the composition.

15 Lubricants reduce friction between the material to be compressed and die wall during compression and ejection. Most lubricants are water insoluble and include stearates (magnesium, calcium and sodium), stearic acid, talc and waxes. Water soluble lubricants include PEG's, sodium benzoate, sodium oleate, sodium acetate, sodium lauryl sulfate and magnesium lauryl sulfate.

20 25 Lubricant levels are from about 0% to 5% by weight of the composition.

Colorants are added to help identify types of vaccine formulations such as in the form of tablets for aesthetic and functional purposes, for example and not as limitation to the present invention, the dyes disclosed in Examples A through D taken from Israeli Patent No. 46189.

30 Colorant levels are from about <1% of the formulation.

35

The vaccine compositions of the present invention can be tableted according to methods known to those skilled in the art, such as described in *Pharmaceutical Dosage Forms, Tablets*, 2nd. Ed. 1989, Vols 1, 2, 3, Editors H. A. Lieberman, L. Lachman, J. B. Schwartz.

In a preferred embodiment, the composition of the present invention is a hard tablet prepared having an effervescent agent as a dissolution aid. As those skilled in art appreciate, the effervescent tablet must contain a basic component and an acidic component, such as an effervescent pair, so that upon dissolution appropriate reactions occur to generate carbon dioxide and carbonic acid. Suitable effervescent components include the carbonate family of basic compounds and inorganic or organic acidic compounds.

Among the carbonate family of basic compounds, preferred effervescent agents for use in the compositions of the present invention are sodium carbonate, sodium bicarbonate, glycine carbonate, potassium carbonate, potassium bicarbonate, potassium dihydrogencitrate, and calcium carbonate. A most preferred basic compound is sodium bicarbonate.

Preferred acidic components for use in the compositions of the present invention are citric acid, adipic acid, tartaric acid, maleic acid, boric acid, benzoic acid, hydroxybenzoic acid, methoxybenzoic acid, mandelic acid, malonic acid, lactic acid, pyruvic acid, glutaric acid, aspartic acid, hydrochloric acid, oxalic acid, salicylic acid, succinic acid, and acetic acid. A most preferred acidic effervescent component is citric acid.

In addition to the basic and acidic effervescent tablet ingredients described above, the tablet composition of the present invention may also contain other excipients conventionally employed.

-25-

The tablet compositions of the present invention are obtained using tableting procedures known in the art. Generally, the tableting procedures used for the present invention may be summarized as follows: the ingredients were sieved, blended 5 and directly compressed into tablets of the required weight, size and hardness on a MANESTY F3 tablet press.

The effervescent tablet compositions of the present invention may be dissolved in ordinary water or a simple saline solution.

10

Antigenic vaccine components are those components that specifically trigger the immune response against the antigen or antigens from which the vaccine components were derived. Such components may originate from one virus or microorganism 15 including recombinants e.g. an antigenic lipoplysaccharide and an antigenic protein, or e.g., two different antigenic proteins. They may also comprise antigenic parts of the protein or polysaccharide. These components are generally referred to as subunit components. In some cases the vaccine 20 component comprises the whole virus or microorganism including recombinants. The vaccine component can for example be a bacterin, or a live attenuated bacterium or virus, an inactive bacterium or virus, or a dead bacterium or virus including recombinant and otherwise modified. 25 Preferably, a vaccine component is a live (modified nonvirulent or partially virulent including recombinant) bacterium or virus. Examples include, but are not limited to, *Salmonella* bacteria, New Castle disease virus, Infectious Bursal Disease (Gumboro) virus, Infectious Bronchitis virus, 30 Pseudorabies virus or anthrax spore vaccine.

Combination vaccines are vaccines comprising various vaccine components. Combination vaccines may also comprise antigenic components derived from two or more different viruses or 35 microorganisms.

- 26 -

More complex combinations are also possible. Thus, vaccines of one of the types described above, as well as mixtures thereof are referred to as combination vaccines. These can also contain any of the known adjuvants.

5

A "package" is understood to be any package useful for the storage of a stable compressed vaccine preparation.

10 The package may, for example and not as a limitation, be a glass or plastic (e.g., a high-density polyethylene) container generally used for packaging and storage of tablets. Adding the stable compressed freeze dried vaccine preparation to a diluent to homogeneously dissolve the preparation would suffice to make the vaccine ready for use.

15 Another form of packaging for compressed freeze dried vaccine preparations of the subject invention is a blister pack. One example of a blister pack are plastic sheets, with rows of pits (trays) which contain the preparations and are heat sealed with aluminum foil lidding preferably under dry nitrogen. Another variety of blister pack useful for sensitive products are so-called aluminum/aluminum blisters where both tray and lidding are based on aluminum or aluminum laminates with various plastics. This would avoid the use of expensive and space consuming glass vials, generally used for 20 packaging and storage of vaccines for which the eventual user generally has no use.

25 The present invention makes it possible to add one or more compressed freeze dried vaccine compositions directly from a blister pack to e.g., a bucket of water to be used in the drinking water or aerosol spraying system to ensure successful vaccination. This is usually accomplished on-site, for example in a chicken shed. Veterinary vaccination can also be achieved by fogging, vent brush, piercing, whole 30 body spray or as eye drops. The vaccine solution obtained in a similar manner might be used alternatively for in-ovo immunization of embryos as described in U.S. Patent Nos. 35 5,397,569 and 5,871,748.

-27-

It is clear that any device that can be used to contain compressed solids can be used in the invention. A diluent may be just water, or on the other hand it may be a complex mixture of buffers and adjuvants. This will 5 depend mainly on which additives have been added to the solution prior to lyophilization or to the preparation prior to compression.

Known freeze drying methods yield a cake comprising the 10 vaccine component or components in a vial. This method is space and time-consuming, as mentioned. If the antigenic vaccine component or components are freeze dried in trays of solution, then the whole surface of the cold plates in the freeze drying machine is utilized during the process. 15 Additionally, should collapse occur, or for that matter if there is any other problem in the freeze drying process, the material can be easily recovered. This is not the case if the material was pre-filled into glass vials prior to lyophilization. Additionally, since no height consuming 20 vials are involved in this part of the process, the cold plates can be stacked up to a high-density. As a result, the capacity of freeze dryers substantially increases, limited practically only by condenser capacity. As a corollary, much smaller freeze dryers could be used for the present invention 25 to achieve the same output as when vials are used in much larger dryers.

Therefore, in one preferred embodiment, the vaccine 30 composition is compressed from sterile lyophilized antigenic material which has been dried in trays and then broken into powder and admixed with sterile additives to aid tabletting and eventual dissolution. The sterile vaccine composition is then packaged under dry nitrogen gas in a sterile blister strip pack with a high moisture and gas barrier.

-28-

In one preferred embodiment, the lyophilized material is a live attenuated virus.

5 In another preferred embodiment, an admix comprising a combination of previously dried virus components is compressed into a single preparation together with additives to aid dissolution and optionally those adjuvants desired for inoculation.

10 If a combination vaccine is required, the advantages offered by the present invention are even more pronounced. It suffices to simply add sufficient pre-titrated lyophilisate of each type of antigenic vaccine component to the preparation before compression to achieve a combination 15 vaccine with each component in a highly accurate dose.

At the same time, the present invention offers a solution to the problem of the large storage capacity needed to store all possible variants of e.g., a three or four component vaccine.

20 Instead of mixing the various components prior to freeze drying as may be required for the freeze drying of combination vaccines, each component is freeze dried separately. Thus the various components can be stored 25 separately. When necessary, each desired combination is easily made by admixing the appropriate amount of lyophilized material of each desired component into one preparation as described herein, and then compressing and packaging the mixture as described.

30 This allows for example, in the case of a 4-component combination vaccine, stocking only four containers, each only containing lyophilized material of one specific vaccine type to compose any single or combination vaccine preparation that is 35 required. Previous methods would require 15 different containers, each comprising a prefabricated component or mixture.

-29-

- In yet another preferred embodiment, the vaccine container comprises a sterile blister strip containing solid forms, such as sterile tablets compressed from lyophilized material of one or more vaccine components admixed with a sterile dissolution aid in an effervescent pair (e.g., sodium bicarbonate and citric acid) a sterile binder (e.g., polyvinylpyrrolidone) and a sterile lubricant (e.g., sodium stearyl fumarate, magnesium stearate). These single or multiple component preparations can then be used to easily prepare *in situ* an accurate vaccine solution of known titer.
- The foregoing are examples for the dissolution aid, binder and lubricant, and are not to be taken as a limitation for the vaccine composition of the present invention.
- In yet another embodiment, the vaccine composition and method of immunization comprises a vaccine composition with components derived from two or more antigenic components. A vaccine based on components from multiple antigenic components has the advantage that a single administration of such a vaccine suffices to induce protection against multiple diseases. It should be understood that for each virus or microorganism, any of several different antigenic vaccine components may be included.
- In yet a further embodiment, the antigenic components for each vaccine can be mixed in the exact ratios needed to form a complex required for *in-ovo* immunization such as live Marek's disease, NDV and Gumboro vaccines. Multicomponent *in-ovo* vaccine preparations are therefore also possible. The dosage form for such a combination can be achieved by the present invention by compressing an admixture of the freeze dried antigenic components for each disease, and the required antibodies together with the tabling aids. Such a preparation could then be used to achieve the desired virus immunizing factor complex *in situ* by dissolution of the preparation in the required vehicle and under stipulated conditions directly prior to *in-ovo* inoculation.

-30-

Usually, the vaccine container can contain between 1 and 10,000 doses or more of vaccine. Single dose containers are common for individual vaccination, both for human and veterinary use.

5

Human Poliovirus vaccine, human live freeze dried Typhoid vaccine or Canine Parvovirus vaccine are typically formulated as single dose vaccines. It should be understood, that for a single dose of vaccine, similar formulation procedures as 10 described for multi-dose vaccines fully apply.

For the vaccination of large sheds of newly hatched chickens, it is common practice to use a 10,000 dose vaccine container for mass vaccination against Infectious Bronchitis virus or 15 NDV. For the vaccination of large farm animals such as cattle, against e.g., Infectious Bovine Rhinotracheitis or Parainfluenza virus, vaccine containers with 10 doses are commonly used.

20

One of the advantages of the vaccine compositions prepared according to the present invention, is that dissolution aids which may have been incompatible in the freeze dried solution, can be included after lyophilization. This speeds the administration procedure. It has unexpectedly been found 25 that the use of citric acid as part of an effervescent pair, which was expected to be detrimental to the live attenuated virus preparations, had no significant impact on the titers.

30

It should also be apparent that the integrity of the moisture barrier for the container has a significant effect with formulations of this type and steps should be taken to ensure that an effective moisture barrier is formed in the packaging. This is particularly true when employing blister strip packaging and where the additives selected are potentially destabilizing when wet, as is the case with 35 citric acid.

-31-

The present invention also provides a method of immunizing a subject against a disease comprising the steps of: dissolving a vaccine composition with a diluent to form a solution, wherein the vaccine composition comprises at least one lyophilized antigenic component and a dissolution aid, wherein the vaccine composition is in the form of a hard tablet, and wherein the vaccine composition provides protection against such disease; and administering the resulting solution to the subject in an amount effective to 10 immunize the subject against the disease.

Alternatively, the lyophilisates may comprise antigenic vaccine components which were derived from two or more viruses or microorganisms.

15 In addition, the present invention provides a vaccine composition wherein the vaccine composition and a diluent are contained together in a package. Such an embodiment allows for a method of immunization where a dissolving step to form 20 a liquid vaccine for administration can occur in situ in the field.

It should be understood that a vaccine package or pack containing the compressed freeze dried stable vaccine 25 composition may be any useful packaging of a vaccine. In a simple form, the vaccine pack comprises a vaccine container comprising the vaccine components, packed together with instructions in a box. In a more complex form of a vaccine pack, the vaccine container could additionally comprise a 30 diluent and a syringe. In an additional embodiment, the compressed lyophilized vaccine is packed under sterile conditions into a sealed syringe, where the dissolution of the vaccine can thus occur inside the sterile syringe. In this way the batch size of pre-filled syringes is not 35 dependent on the space occupied by syringes in the lyophilizer.

-32-

The following examples illustrate preparation and potency of the vaccine composition of the present invention when used to immunize a subject against various infectious diseases. Stability evaluations with a titer analysis of a compressed freeze dried tablet form for various vaccine formulations are also presented.

The examples are presented to further illustrate and explain the present invention and should not be taken as limiting in any regard. Unless otherwise indicated in the examples and elsewhere in the specification and claims, all parts and percentages are by weight. Temperatures are in degrees Centigrade.

15

EXAMPLE 1

1.1 Preparation of Tablets Comprising Live Attenuated Newcastle Disease Virus VH Strain (Hereinafter NDV-VH)

20

Fertile, specific-pathogen-free (SPF) eggs were inoculated with NDV and incubated according to known methods for propagation of NDV viruses in eggs.

25

Allantoic amniotic fluid (AAF) was harvested and purified by centrifugation at 4000g for 20 min.

Lyophilization in vials was performed fully according to known, standard procedures.

30

Tablets were prepared in the following manner:

To 13.2 g of pulverized lyophilisate was added:

60g sodium bicarbonate

42g citric acid anhydrous

4.2g polyvinylpyrrolidone K-30

35

0.3g magnesium stearate

The ingredients were then mixed and tablets were punched each with a weight of 400 mg.

-33-

Each resultant tablet thus prepared contained 44 mg of the lyophilizate.

1.2 Analysis of Tablets

5

The titer in SPF eggs of a random sampling of the tablets was evaluated and compared to the adjusted amount of the lyophilisate in the vials.

10	NDV-VH/tablet	10 ^{5.7} EID ₅₀ *
	NDV-VH/vial	10 ^{5.4} EID ₅₀

*Egg infectious dose 50 units.

When one tablet was added to 100 ml of water, dissolution was complete in less than one minute, i.e. no trace of solid was visible to the naked eye.

When one tablet was added to 10 ml of water, dissolution was complete in 70 seconds.

20

When one tablet was added to 2 ml of water, dissolution was complete after 80 seconds.

25

In 1 ml of water, although complete dissolution was achieved, the effervescent nature of this tablet was not found to be involved in the full dissolution, which had taken approximately 4 minutes.

1.3 Packaging and Stability

30

The tablets were packed in Polyvinyl chloride (PVC) blister strips and stability tested at 37°C and found to be relatively stable over 5, 7 and 9 day periods.

35

-34-

Days at 37°C	zero	5	7	9
NDV-VH tablet	10 ^{5.7}	10 ^{5.2}	10 ^{5.3}	10 ^{5.4}

5

Storage at 4°C produced no appreciable change in titer and color of tablets after nine months.

10	Months at 4°C	zero	3	9
NDV-VH tablet	10 ^{5.7}	10 ^{5.3}	10 ^{5.3}	10 ^{5.3}
NDV-VH vial	10 ^{5.6}	10 ^{5.6}	10 ^{5.6}	10 ^{5.6}

15 Titters given are in EID₅₀ units per tablet or vial calculated for the same amount of active material.

1.4 Potency Test of the Tableted NDV-VH in Chickens

20	Group	NDV-VH	EID ₅₀ /Dose	HI at 3 weeks Post-Vaccination	Mortality after challenge
A	tablet 1	10 ^{5.6}	9.3	2/18	
B	tablet 2	10 ^{5.5}	9.2	1/20	
C	vial	10 ^{5.6}	9.2	2/19	
D	non-vaccinated	--	1.2	10/10	

25 HI = Haemagglutination inhibition units.

A: A tablet of NDV-VH was dissolved in 20 ml of sterile distilled water and 0.02 ml was used to vaccinate each of the 18 chicks (4 weeks old, kept in isolators) by eye drops.

30

-35-

B: Another group of chicks was similarly vaccinated with the tableted VH vaccine dissolved in 40 ml of sterile distilled water.

5 C: A vial of NDV-VH was dissolved in sterile distilled water to give the same virus concentration as in A.

D: Non vaccinated control.

10 At three weeks post vaccination the birds were bled for antibodies titration by the Haemagglutination inhibition (HI) test and all the groups were challenged with viscerotropic velogenic NDV given by i.m. Injection at $10^{3.3}$ EID₅₀/bird at
15 the Kimron Veterinary Institute (The Israeli Veterinary Services).

The results of the tests indicate that good protection is being provided to the chickens by all the vaccine preparations tested.

20

EXAMPLE 2

2.1 Preparation of Tablets Comprising NDV -VH
Fertile, SPF eggs were inoculated with NDV and incubated
25 according to known methods for propagation of NDV viruses in
eggs.

AAF was harvested and purified by centrifugation at 4000g for
20min. Lyophilization was performed fully according to known,
30 standard procedures.

NDV-VH virus was lyophilized in a tray. The dried powder was sealed under low humidity in a sterile double polypropylene bag and kept at -20°C. Effervescent tablets containing
35 increasing contents of dried powder were produced. Tablets were prepared according to the procedure described in Example 1.

-36-

	Composition	Wt. (g)	Wt. (g)	Wt. (g)	Wt. (g)
5	VH Lyophilized tray dried	1.25 (2.7%)	2.5 (5.3%)	5.0 (10.1%)	10.0 (20.3%)
	Sodium Bicarbonate	25.0	25.0	25.0	22.0
10	Citric Acid Anhydrous	17.5	17.5	17.5	15.4
	Polyvinyl- pyrrolidone K-30	1.75	1.75	1.75	1.75
15	Magnesium Stearate	0.12	0.12	0.12	0.12
	Tablet weight	0.5	0.45	0.38	0.36

2.2 Analysis of Tablets

NDV-VH titers (EID₅₀) in the tablets were obtained by titrations in SPF eggs.

25	Percent lyophilisate/ tablet	2.7	5.3	10.5	20.3
	NDV-VH /tablet	10 ^{2.00}	10 ^{4.00}	10 ^{7.75}	10 ^{9.00}

Satisfactory linear relationship was obtained between active material concentrations and virus titers.

When one tablet was added to 100ml of water, dissolution was complete in less than one minute, i.e. no trace of solid was visible to the naked eye.

-37-

2.3 Packaging and Stability

The tablets were placed in syringes, which were packed in aluminum laminate sachets. An injectable solution was
5 prepared by sucking the diluent for injection into the syringe, followed by complete dissolution of the tablet. The resulting injectable solutions were used either directly, for individual vaccination, or alternatively for multiple vaccination after further dilution in a larger container.
10 An automatic syringe was then applied.

EXAMPLE 3

3.1 Preparation of Tablets Comprising NDV-VH Containing Antibodies Against Newcastle Virus (NDA) for In-Ovo Vaccination

Fertile, SPF eggs were inoculated with NDV and incubated according to known methods for propagation of NDV viruses in
20 eggs.

AAF was harvested and centrifuged at 4000g for 20 min. Lyophilization was performed fully according to known, standard procedures and the lyophilized material titrated. The desired amounts of NDV and NDA were determined.
25 Tablets were prepared in the following manner:

To 7.0g of pulverized lyophilisate was added:
0.36g lyophilised hyperimmune chicken serum for NDV (NDA)
13g sodium bicarbonate
30 9.1g citric acid anhydrous
0.9g polyvinylpyrrolidone K-30
0.07g magnesium stearate

The ingredients were then mixed and tablets were punched each
35 with a weight of 500 mg. Each tablet thus prepared contained 115 mg of the lyophilized virus preparation.

-38-

3.2 Analvsis of the Tablets

When one tablet was added to 100ml of water, dissolution was complete within 2.5 min, i.e. no trace of solid was visible
5 to the naked eye.

3.3 Packaging

The tablets were packed in PVC blister strips.
10

3.4 Potency Test of Tableted NDV-VH with NDA In-Ovo

In-ovo vaccination of commercial broiler chicks with NDV-VH + NDA. Challenge of In-ovo vaccinated chicks at 2 and 4 weeks post hatching was conducted. The embryos were injected in a commercial farm by an Inovoject apparatus (Embrex U.S.A.) at 18 days of incubation. A tablet was dissolved in 200 ml of Marek's vaccine diluent and 0.05 ml was injected into each egg. Both vaccinated and non-vaccinated chicks
15 were kept in isolators to avoid non-specific contamination
20 by NDV viruses.

	HI at 2 weeks	% Mortality at 2 weeks challenge	HI at 4 weeks	% Mortality at 4 weeks challenge
Vaccinated	5.7	40	4.4	10
Non- vaccinated	3.4	53	2.5	80

At 2 and 4 weeks chicks were bled for antibodies detection by the HI test and both groups were challenged with
30 viscerotropic velogenic NDV given by I.M. injection of $10^{5.3}$ EID₅₀/bird at the Kimron Veterinary Institute (The Israeli Veterinary Services). The results indicate that good protection was provided to the chicks at 4 weeks post hatching.

-39-

EXAMPLE 4

4.1 Preparation of Tablets Comprising Live Attenuated Gumboro Disease Virus (Hereinafter "MB")

5

SPF eggs were inoculated with Gumboro (MB) disease virus and incubated according to known methods for propagation of viruses in eggs.

10 Embryos and chorioallantoic membranes were harvested and the virus was extracted by homogenization.

Lyophilization was done fully according to known, standard procedures.

Tablets were prepared in the following manner:

15 To 10.0g of pulverized lyophilisate was added:
22.4g sodium bicarbonate
15.7g citric acid anhydrous
1.7g polyvinylpyrrolidone K-30
0.1g magnesium stearate

20

The ingredients were then mixed and tablets were punched each with a weight of 350 mg.

25 Each tablet thus prepared contained 70 mg of the lyophilisate.

4.2 Analysis of Tablets

30 The titer of a random sampling of the tablets was evaluated as $10^{5.6}$ EID₅₀/tablet.

($10^{4.5}$ EID₅₀ is considered to be a vaccinating dose).

35 When one tablet was added to 100 ml of water, dissolution was complete in less than one minute, i.e. no trace of solid was visible to the naked eye.

Virus titers in effervescent tablets and vials

-40-

MB/tablets	$10^{5.1}$ EID ₅₀
MB/vials*	$10^{5.5}$ EID ₅₀

* Adjusted to the same quantity of immunizing material.

5 4.3 Packaging and Stability

The tablets were packed in PVC blister strips and stability tested at 37°C.

Days at 37°C	zero	5
MB	$10^{5.4}$	$10^{4.8}$

EXAMPLE 5

15 5.1 Preparation of Effervescent Tablets Containing Fowl Pox Live Vaccine Virus

SPF eggs were inoculated with Fowl Pox disease virus and incubated according to known methods for propagation of viruses in eggs.

20 Embryos and chorioallantoic membranes were harvested and the virus was extracted by homogenization.

25 Lyophilization was performed fully according to known procedures.

700 mg tablets were prepared substantially as described in Example 1.

30 Each tablet contained 140 mg of lyophilisate.

5.2 Analysis of Tablets

35 The titer of each tablet was evaluated in SPF eggs and was found to be $10^{6.2}$ EID₅₀/tablet. When one tablet was added to 100 ml of water, dissolution was complete in two minutes, i.e. no trace of solid was visible to the naked eye.

-41-

EXAMPLE 6

6.1 Preparation of Effervescent Tablets Containing
5 Laryngotracheitis (Fowl) Live Virus

SPF eggs were inoculated with Laryngotracheitis vaccine virus and incubated according to known methods for growing viruses in eggs. Embryos and chorioallantoic membranes were 10 harvested and the virus was extracted by homogenization.

Lyophilization was performed fully according to known procedures. 700 mg Tablets were prepared substantially as described in Example 1.

15 Each tablet contained 140 mg of lyophilizate. The titer of each tablet was evaluated in SPF eggs and was found to be $10^{3.53}$ EID₅₀.

EXAMPLE 7

20 7.1 Preparation of Effervescent Tablets Containing
 Infectious Bronchitis of Poultry Live Virus

SPF eggs were inoculated with Infectious Bronchitis of 25 Poultry disease virus and incubated according to known methods for growing viruses in eggs. Embryos and chorioallantoic membranes were harvested and the virus was extracted by homogenization.

30 Lyophilization was performed fully according to known procedures.

700 mg tablets were prepared substantially as described in Example 1.

35 Each tablet contained 140 mg of lyophilisate.

-42-

7.2 Analysis of Tablets

The titer of each tablet was evaluated in SPF eggs and found to be $10^{6.22}$ EID₅₀/tablet.

5

EXAMPLE 8

8.1 Preparation of Effervescent Tablets Containing Gumboro Winterfield (Fowl) Live Virus

10

SPF eggs were inoculated with Gumboro Winterfield (Fowl) disease virus and incubated according to known methods for propagating viruses in eggs.

15

Embryos and chorioallantoic membranes were harvested and the virus was extracted by homogenization.

Lyophilization was performed fully according to known procedures.

20

700 mg tablets were prepared substantially as described in Example 1.

Each tablet contained 140 mg of lyophilizate.

25

8.2 Analysis of Tablets

The titer of each tablet was evaluated in SPF eggs and found to be $10^{6.22}$ EID₅₀/tablet.

30

EXAMPLE 9

9.1 Preparation of Effervescent Tablets Containing Infectious Bronchitis (IB-HI20) + NDV-VH (Fowl) Live Virus

35

-43-

SPF eggs were inoculated with IB-HI20 or with NDV-VH disease virus and incubated according to known methods for propagating of viruses in eggs.

5 AAF was harvested and centrifuged at 4000/g for 20 min. Lyophilization was performed fully according to known procedures.

10 700 mg tablets were prepared as substantially described in Example 1.

Each tablet contained 140 mg of lyophilizate.

9.2 Analysis of Tablets

15 When one tablet was added to 100 ml of water, dissolution was complete within 2 min, i.e. no trace of solid was visible to the naked eye.

20 The titer of each tablet was evaluated in SPF eggs and found to be $10^{5.6}$ and $10^{5.5}$ EID₅₀/tablet for IB-HI20 and NDV-VH (Fowl) respectively.

EXAMPLE 10

10.1 Preparation of Effervescent Tablets Containing Sheep Pox Live Virus

30 Virus propagation was performed in Vero cells grown in plastic rollers.

Lyophilization was performed fully according to known procedures.

35 700 mg Tablets were prepared substantially as described in Example 1.

Each tablet contained 140 mg of lyophilizate

-44-

10.2 Analysis of Tablets

The titer of each tablet was evaluated as $10^{5.5}$ TCID₅₀/tablet. Sheep pox vaccine's virus was titrated in Vero cells .

5

EXAMPLE 11

11.1 Preparation of Effervescent Tablets Containing Rinderpest Live Vaccine Virus (Cattle)

10

Virus propagation was performed in Vero cells grown in plastic rollers.

15

Lyophilization was performed fully according to known procedures.

700 mg Tablets were prepared substantially as described in Example 1.

20

Each tablet contained 140 mg of lyophilizate.

11.2 Analysis of Tablets

The titer of each tablet was evaluated as $10^{4.5}$ TCID₅₀/tablet.

25

Rinderpest vaccine's virus was titrated in Vero cells.

11.3 Color Coding of Vaccine Compositions

30 Israeli Patent No. 46189 discloses poultry color-coded virus vaccine stained with a distinctive dye, which is safe in life tissues and which does not harm the viability of viruses. The different vaccines are each color-coded by means of a different distinctive dye. Suitable dyes are, for example, amaranth red dye, tartrazine yellow, indigo carmine blue or mixtures of any of these, resulting in distinctive hues.

35

-45-

A process of coloring the various different types of vaccines (or color-coding) of vaccines in different contrasting colors is useful against mistakes that have been made by farmers who have vaccinated their poultry flocks with a different 5 type vaccine than the one intended, thereby exposing their unprotected flocks against the disease which they had actually intended to immunize. Such mistakes are usually discovered only too late, if at all, and in various cases have brought in complaints against the vaccine, in addition 10 to serious financial losses and damages to the farmer. Chemical colors, however, safe as they may be by themselves, pose several problems and dangers when combined with a virus vaccine.

15 Vaccination of poultry involves the use of live virus vaccines in which a culture of live viruses are contained in the final product, and since live viruses are very delicate and may deteriorate easily, the technical problem is quite involved. Different coloring agents and dyes are 20 known to be chemically active, namely they may oxygenate or reduce chemically. Live viruses are very sensitive to changes in the environment such as pH conditions, temperature, radiation, different metal ions and otherwise may be affected by chemical agents with which they come in 25 contact. Such dyeing agents as methylene blue, or fuschin red or aniline dyes may be toxic to the viruses and possibly pose problems with the chickens or turkeys into which they would be injected. It was therefore necessary to choose such dyes that will be safe for use in live tissues and will not 30 harm the viability of the viruses with which they are in contact. Four color shades have been chosen to identify the four most popular and important vaccines used in the poultry industry at present, namely a red color to identify Newcastle Disease vaccine of the lentogenic strain, or as it is called 35 in Israel, the Komarov "chick" strain; a yellow color to identify the Newcastle Disease vaccine of the Komarov-Haifa or "pullet" strain; a blue color to identify the

-46-

Laryngotracheitis vaccine; and a green shade to identify the Fowl Pox vaccine.

As disclosed in Israeli Patent No. 46189, different
5 concentrations of these dyes were tried and were mixed directly with the wet vaccine before it was dispensed into the final containers and before it was desiccated (lyophilized). Several tests were run to ascertain that these dyes will not harm the vaccine.

10

Different batches of dyed vaccines were subjected to storage conditions under refrigeration and otherwise and repeatedly titrated to verify the virus concentration. Ample controls of the vaccine without the addition of the dyes were run
15 parallel to every test done on the dyed vaccine. Dyed vaccines have also been tested directly on live birds to see what effect they might have. Repeat tests with all four types of vaccines and four dyes used in these experiments have shown no detrimental effect on the virus titration
20 results. Injection trials in live birds and the application of the virus vaccines by other routes such as through the drinking water; by the stick method through the skin (Fowl Pox); and by the vent-brush method (for laryngotracheitis vaccine) have shown that the dye had no detrimental effect
25 on the birds and when injected intramuscularly it was reabsorbed from tissues and completely disappeared within 36 hours. Israeli Patent No. 46189 discloses vaccines tested in the field on several flocks which were vaccinated from one day of age and up to marketing age with these dyed vaccines.
30 These birds were successfully marketed and had no evidence of the dyes whatsoever.

Further details of the invention disclosed in Israeli Patent No. 46189 may be readily understood in connection with the
35 description given in the following examples taken therefrom, and which have been selected for the purpose of illustration only in order to enable one skilled in the art to use the

-47-

color-coded formulations for vaccines, and thus are not limitations upon the invention.

5

EXAMPLE A

AMARANTH red dye was prepared for combination with Vineland Newcastle "chick" vaccine, by making a concentrate-dye-solution. This concentrate contained 145 grams of dry 10 powdered dye dissolved in 4 liters of distilled water. The concentrated dye solution was autoclaved at 20 psi for 20 minutes shortly after preparation and was stored in sealed glass bottles in a dark place. The dye-concentrate solution was added at 1.33% to the final Vineland Newcastle-Chick- 15 Vaccine.

Results of the titrations with dyed vaccine compared to undyed controlled have been found to be as follows:

20 Titrations 2 weeks after lyophilization:

without dye $10^{9.5}$ S.D. 50/mi

with dye $10^{9.3}$ "

Accelerated titration:

25 without dye $10^{9.1}$ "

with dye $10^{9.1}$ "

Titration 30 days after lyophilization:

without dye $10^{9.16}$ "

30 with dye $10^{9.3}$ "

Titration 3 months after lyophilization:

without dye $10^{9.56}$ "

with dye $10^{9.3}$ "

35

-48-

Titration done 6 months after lyophilization
only sample
with dye $10^{9.16}$ "

5

EXAMPLE B

TARTRAZINE yellow dye was prepared for combination with
Vineland Newcastle Pullet Strain Vaccine (The Mesogenic
Haifa-Komorav Strain), by making a concentrate-dye-solution.
10 This concentrate contained 200 grams of dry powdered dye
dissolved in 3 liters of distilled water. The concentrated-
dye-solution was autoclaved at 20 psi for 20 minutes shortly
after preparation and was stored in sealed glass bottles in
a dark place. The dye-concentrate solution was added at 3%
15 to the final Vineland Newcastle Pullet Vaccine.

Results of the titrations with dyed vaccine compared to
undyed controls have been found to be as follows:

20 Results of regular vaccine titration:
 $10^{9.4}$ EID₅₀ per milliliter
Results of titrated sample with dye: $10^{6.5}$

Titration after 7 days incubation at 37°C:
25 without dye $10^{7.3}$ EID_{50/ml}
with dye $10^{7.2}$ "

Titration 39 days after lyophilization:
without dye $10^{5.66}$ "
30 with dye $10^{5.9}$ "

Titration 93 days after lyophilization:
without dye $10^{5.66}$ "
with dye $10^{5.66}$ "

-49-

7 1/2 months after lyophilization:
without dye $10^{6.5}$ "
with dye $10^{6.7}$ "

5

EXAMPLE C

INDIGO-CARMINE blue dye was prepared for combination with Vineland-Injections Laryngotracheitis Vaccine, by making a concentrate-dye-solution.

10

This concentrate contained 200 grams of dry-powdered dye dissolved in 3 liters of distilled water. The concentrate dye solution was autoclaved at 20 psi for 20 minutes shortly after preparation and was stored in sealed glass bottles in
15 a dark place. The dye concentrate solution was added at 3% to the final Vineland Injections Laryngotracheitis Vaccine.

20

Titration 3 weeks after lyophilization:
without dye $10^{6.3}$ EID50/ml
with dye $10^{6.1}$ "

25

Accelerated titration:
without dye $10^{5.1}$ "
with dye $10^{4.5}$ "

30

Titration 30 days after lyophilization:
without dye $10^{6.0}$ "
with dye $10^{5.8}$ "

35

Titration 3 months after lyophilization:
without dye $10^{5.6}$ "
with dye $10^{5.5}$ "

-50-

Titration 7 months after lyophilization:

without dye $10^{5.5}$ "

with dye $10^{5.6}$ "

- 5 (This is a somewhat unusual drop in titre for both dyed and undyed samples and accelerated batched showed more than 1 log drop on acceleration indication possible high moisture content in this batch.)

10

EXAMPLE D

15

A green shade dye coded "P" (for Pox) was obtained by mixing INDIGO-CARMINE with TARTRAZINE dyes and was used for combination with Vineland Fowl Pox Vaccine. 100 grams of powdered dye mix was dissolved in 3 liters of distilled water.

Same procedure was used as in examples No. 2 and No. 3 and the solution was added at 3% to the final Fowl Pox vaccine.

20

Results of the titrations with dyed vaccine compared to undyed controls have been found to be as follows:

7 days after lyophilization

undyed control: $10^{5.5}$ EID 50/mL

25

vaccine with dye: $10^{5.7}$ " "

3 months later

undyed control: $10^{5.4}$ EID 50/mL

vaccine with dye: $10^{5.5}$ " "

30

6 months later

undyed control: $10^{5.25}$ " "

vaccine with dye: $10^{5.3}$ " "

9 months after production

undyed control: $10^{3.1}$ " "

35

vaccine with dye: $10^{5.3}$ " "

-51-

The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the invention, and is not intended to detail all those obvious modifications and variations of it, which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present invention, which is defined by the following claims.

10

15

20

25

30

35

-52-

What is claimed is:

1. A stable compressed vaccine composition comprising at least one lyophilized antigenic component and a dissolution aid.
5
2. The vaccine composition of claim 1, wherein the compressed vaccine composition is in the form of a hard tablet.
10
3. The vaccine composition of claim 1, wherein the composition dissolves completely and rapidly in water.
15
4. The vaccine composition of claim 1, wherein the composition is sterile.
20
5. The vaccine composition of claim 1, wherein the dissolution aid is an effervescent agent or pair of agents, a disintegrant, a surfactant, or a solubilizer.
25
6. The vaccine composition of claim 5, wherein the dissolution aid comprises a pair of effervescent agents.
30
7. The vaccine composition of claim 6, wherein the effervescent pair comprises a salt and an acid.
35
8. The vaccine composition of claim 7, wherein the acid is citric acid and the salt is a bicarbonate.
9. The vaccine composition of claim 1, wherein the lyophilized component comprises up to 80% by weight of the composition.
10. The vaccine composition of claim 1, wherein the composition is characterized by complete dissolution within less than 80 seconds upon contact with a diluent.

-53-

11. The vaccine composition of claim 10, wherein the complete dissolution occurs at a diluent to composition ratio of between 0.5 ml of diluent per 200 mg of composition and 100 ml of diluent per 400 mg of composition.
5
12. The vaccine composition of claim 1, wherein the stability of the composition is characterized by a loss of titer no greater than the difference between 10^{5.7} EID₅₀/ml and 10^{9.2} EID₅₀/ml after 5 days at 37°C .
10
13. The vaccine composition of claim 1, wherein the stability of the composition is characterized by a loss of titer no greater than the difference between 10^{3.7} EID₅₀/ml and 10^{9.3} EID₅₀/ml after 9 months at 4°C.
15
14. The vaccine composition of claim 1, further comprising a binder and a lubricant.
- 20 15. The vaccine composition of claim 1, wherein the composition disintegrates completely and rapidly in water.
- 25 16. The vaccine composition of claim 1, wherein the active material is a pre-titrated lyophilizate that is kept under a dry nitrogen atmosphere below a freezing temperature prior to use.
30
17. The vaccine composition of claim 1, wherein the antigenic component is a whole virus or a whole microorganism.
35
18. The vaccine composition of claim 1, wherein the antigenic component is a live bacterium or a live virus.

-54-

19. The vaccine composition of claim 18, further comprising an indicator of the presence of the antigenic component.
20. The vaccine composition of claim 19, wherein the indicator is a dye.
5
21. The vaccine composition of claim 1, wherein the antigenic component comprises a lipopolysaccharide or a protein.
10
22. The vaccine composition of claim 18, wherein the antigenic component is a live virus selected from the group consisting of: Newcastle Disease virus, Newcastle Disease virus VH strain, Infectious Bursal Disease virus, fowl pox virus, Laryngotracheitis virus, Infectious Bronchitis of poultry virus, Gumboro Winterfield virus, Infectious Bronchitis (IB-H120), sheep pox virus, Rinderpest virus, or an admixture of one or more of the foregoing, whether naturally occurring, recombinant or modified.
15
23. The vaccine composition of claim 18, wherein the antigenic component is selected from the group consisting of: anthrax spores, Salmonella spp, E. coli, or an admixture of one or more of the forgoing, whether naturally occurring or recombinant or modified.
20
24. The vaccine composition of claim 18, wherein the antigenic component is a live virus and the composition further comprises neutralizing antibodies against the virus.
25
25. A method of immunizing a subject against a disease comprising the steps of:
30
35 (a) dissolving the vaccine composition of claim 1 which provides protection against such disease with a diluent to form a solution; and

-55-

(b) administering the resulting solution to the subject in an amount effective to immunize the subject against the disease.

- 5 26. The method of claim 25, wherein the dissolving step is further characterized by complete dissolution of the vaccine composition.
- 10 27. The method of claim 26, wherein the complete dissolution occurs at a diluent to composition ratio of between 0.5 ml of diluent per 200 mg of composition and 100 ml of diluent per 400 mg of composition.
- 15 28. The method of claim 26, wherein complete dissolution occurs within less than 80 seconds upon contact with a diluent.
- 20 29. The method of claim 25, wherein the administering step comprises injecting the subject with the solution.
- 25 30. The method of claim 25, wherein the administering step comprises spraying the subject with an aerosol formed from the solution.
- 30 31. The method of claim 25, wherein the administering step comprises applying the solution to the subject in the form of eye drops.
- 35 32. The method of claim 25, wherein the administering step comprises providing the solution by oral ingestion.
33. The method of claim 25, wherein the subject is an avian animal and the disease is selected from the group consisting of Newcastle Disease, Infectious Bursal Disease, fowl pox, Laryngotracheitis, Infectious Bronchitis of poultry, Gumboro Winterfield, and Infectious Bronchitis (IB-H120).

-56-

34. The method of claim 33, whereby the solution is administered to the subject in-ovo.
- 5 35. A package comprising the vaccine composition according to claim 1 or 19.
- 10 36. The package of claim 35, wherein the package is a blister pack.
- 15 37. The package of claim 35, wherein the package is a sterile syringe.
- 20 38. A sterile syringe comprising a compacted vaccine composition, wherein the vaccine composition comprises at least one lyophilized antigenic component and a dissolution aid.
- 25 39. The syringe of claim 38, wherein the compacted vaccine composition is a compressed composition.
40. The syringe of claim 39, wherein the compressed vaccine composition is in the form of a hard tablet.
- 25 41. A method of immunizing a subject against a disease which comprises adding a diluent to the syringe of claim 38, 39 or 40 to form a vaccine solution in the syringe and administering the resulting vaccine solution to the subject.

30

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/22929

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 9/28, 9/30
US CL : 424/474, 475, 477, 480

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/474, 475, 477, 480

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, NPL, MEDLINE, BIOSIS, CAPLUS
search terms: vaccine, antigen?, lyophiliz?, compress?, compact

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97/33531 A1 (UNIGENE LABORATORIES, INC.) 18 September 1997, see the claims.	1-41
Y	US 5,897,852 A (WILDERBEEK et al) 27 April 1999, see the entire document.	1-41
Y	US 5,397,569 A (WHITFILL et al) 14 March 1995, see the claims.	1-41
Y	US 5,336,666 A (NEWAY et al) 09 August 1994, see the entire document.	1-41
Y	US 5,206,219 A (DESAI) 27 April 1993, see the claims.	1-41
Y	US 5,350,741 A (TAKADA) 27 September 1994, see the entire document.	1-41

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 SEPTEMBER 2000

Date of mailing of the international search report

19 OCT 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:
A. R. SALIMI

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/22929

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,472,710 A (KLOKKERS-BETHKE et al) 05 December 1995, see the claims.	1-41